Lin, T., Lee, S. O., Niu, Y., Xu, D., Liang, L., Li, L., . . . Chang, C. (2020). Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9(®) lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem.

Lin, Tzu-Hua, et al. "Correction: Differential Androgen Deprivation Therapies With Anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide Versus Anti-androgen Receptor ASC-J9(®) Lead to Promotion Versus Suppression of Prostate Cancer Metastasis." J Biol Chem 2020.

Lin, Tzu-Hua, et al. "Correction: Differential Androgen Deprivation Therapies With Anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide Versus Anti-androgen Receptor ASC-J9(®) Lead to Promotion Versus Suppression of Prostate Cancer Metastasis." J Biol Chem 2020.